Relationship Impact to SCP Structure
Clinical Study 5.3.1.1 – Biopharmaceutical > Bioavailability (BA)
  5.3.1.2 – Biopharmacetical > Comparative Bioavailability (BA) and Bioequivalence (BE)
  5.3.1.3 – Biopharmacetical > In Vitro - In Vivo Correlation
  5.3.1.4 – Biopharmacetical > Bioanalytical and Analytical Methods
  5.3.2.1 – Pharmacokinetics using human biomaterials > Plasma Protein Binding
  5.3.2.2 – Pharmacokinetics using human biomaterials > Hepatic Metabolism and Drug Interactions
  5.3.2.3 – Pharmacokinetics using human biomaterials > Other Human Biomaterials
  5.3.3.1 – Human Pharmacokinetics (PK) > Healthy Subject Pharmacokinetic (PK) and Initial Tolerability
  5.3.3.2 – Human Pharmacokinetics (PK) > Patient Pharmacokinetic (PK) and Initial Tolerability
  5.3.3.3 – Human Pharmacokinetics (PK) > Intrinsic Factor Pharmacokinetic (PK)
  5.3.3.4 – Human Pharmacokinetics (PK) > Extrinsic Factor
  5.3.3.5 – Human Pharmacokinetics (PK) > Population Pharmacokinetic (PK)
  5.3.4.1 – Pharmacodynamics (PD) > Healthy Subject Pharmacodynamics (PD) and PK/PD 5.3.4.2 – Pharmacodynamics (PD) > Patient Pharmacodynamics (PD) and PK/PD
  5.3.5.1 – [Indication] > Efficacy and Safety > Controlled Clinical Studies
  5.3.5.2 – [Indication] > Efficacy and Safety > Uncontrolled Clinical Studies
  5.3.5.3 – [Indication] > Efficacy and Safety > Analyses of Data
  5.3.5.4 – [Indication] > Efficacy and Safety > Other Studies
  5.3.6 – Postmarketing Experience
Nonclinical Study 4.2.1.1 – Pharmacology > Primary Pharmacodynamics
  4.2.1.2 – Pharmacology > Secondary Pharmacodynamics
  4.2.1.3 – Pharmacology > Safety Pharmacology
  4.2.1.4 – Pharmacology > Pharmacodynamic Drug Interactions
  4.2.2.1 – Pharmacokinetics > Analytical Methods and Validation Reports
  4.2.2.2 – Pharmacokinetics > Absorption
  4.2.2.3 – Pharmacokinetics > Distribution
  4.2.2.4 – Pharmacokinetics > Metabolism
  4.2.2.5 – Pharmacokinetics > Excretion
  4.2.2.6 – Pharmacokinetics > Pharmacokinetic Drug Interactions
  4.2.2.7 – Pharmacokinetics > Other Pharmacokinetic
  4.2.3.1 – Toxicology > Single Dose Toxicity
  4.2.3.2 – Toxicology > Repeat Dose Toxicity
  4.2.3.3.1 – Toxicology > In vitro Genotoxicity
  4.2.3.3.2 – Toxicology > In vivo Genotoxicity
  4.2.3.4.1 – Toxicology > Long Term Carcinogenicity
  4.2.3.4.2 – Toxicology > Short or Medium Term Carcinogenicity
  4.2.3.4.3 – Toxicology > Other Carcinogenicity 4.2.3.5.1 – Toxicology > Fertility and Early Embryonic Development
  4.2.3.5.2 – Toxicology > Embryofetal Development
  4.2.3.5.3 – Toxicology > Prenatal and Postnatal Development
  4.2.3.5.4 – Toxicology > Studies in Which the Offspring are Dosed or Evaluated
  4.2.3.6 – Toxicology > Local Tolerance
  4.2.3.7.1 – Toxicology > Antigenicity
  4.2.3.7.2 – Toxicology > Immunotoxicity
  4.2.3.7.3 – Toxicology > Mechanistic
  4.2.3.7.4 – Toxicology > Dependence
  4.2.3.7.5 – Toxicology > Metabolites
  4.2.3.7.6 – Toxicology > Impurities
  4.2.3.7.7 – Toxicology > Other Toxicity
Products 2.3.P – Drug Product
  3.2.P – Drug Product
  3.2.A.1 – Facilities and Equipment
  3.2.A.2 - Adventitious Agents Safety Evaluation
Active Substances 2.3.S – Drug Substance
  3.2.S – Drug Substance
  3.2.A.1 – Facilities and Equipment
  3.2.A.2 - Adventitious Agents Safety Evaluation
Inactive Ingredients 3.2.P.4 Control of Excipients
  3.2.A.3 Novel Excipients
Indications 2.7.3 Summary of Clinical Efficacy
  5.3.5 Reports of Efficacy and Safety Studies